THERAPEUTICSMD, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.03 USD | 0.00% |
|
+7.98% | -9.78% |
| Mar. 29 | TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 06 | Knight Therapeutics Announces Launch of Bijuva in Canada | MT |
Presenter SpeechLouis Susser (Analysts)Good morning, everyone, and thank you for joining the H...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.78% | 23.41M | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- TXMD Stock
- News TherapeuticsMD, Inc.
- Transcript : TherapeuticsMD, Inc. Presents at H.C. Wainwright Virtual Global Life Sciences Conference, Mar-09-2021 11